NIH-funded research R21 grant

Detecting early syphilis using unique bacterial fragments

Official title: Released peptidoglycan fragments are a biomarker for early stages of syphilis

Funded at Northwestern University at Chicago · NIH-11196339 · Data updated 2026-11-12

This study is looking at a new way to quickly and accurately detect syphilis by using tiny pieces of the bacteria that cause it, which could help people get treated faster than with current tests.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionNorthwestern University at Chicago
NIH-funded
Lab location1 site (Chicago, United States)
Project startAugust 1, 2024
Project endJuly 31, 2026
Funding year2024
Award (this year)$251,918
NIH project number7R21AI185998-02
Project IDNIH-11196339 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals who may have been recently exposed to syphilis or are showing early symptoms of the infection.

Less likely to help

Patients who have been diagnosed with syphilis for an extended period or those who are not at risk of exposure may not benefit from this research.

What this research studies

This research investigates the potential of using fragments of the bacterial cell wall from Treponema pallidum, the bacterium that causes syphilis, as a biomarker for early detection of the infection. By developing a new diagnostic test that identifies these unique peptidoglycan fragments, the goal is to provide quicker and more accurate results than current serological tests, which can take weeks to show a response. The study utilizes advanced culture methods to propagate the bacteria and analyze the fragments shed during its growth, aiming to improve patient outcomes through timely treatment.

Why it matters

Potential benefit: If successful, this research could lead to faster and more accurate diagnosis of syphilis, allowing for immediate treatment and better health outcomes.

How similar studies have gone: While the approach of using peptidoglycan fragments as biomarkers is innovative, similar research has shown promise in other bacterial infections, suggesting potential for success in this area as well.

Where this research is happening

  • Northwestern University at Chicago
    Chicago, United States
    Active

Researchers

  • Principal investigator: Jutras, Brandon Lyon — Northwestern University at Chicago
  • Study coordinator: Jutras, Brandon Lyon

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.